scyphostatin and Fibrosarcoma

Scyphostatin is a specific inhibitor for mammalian neutral magnesium-dependent sphingomyelinase with a fifty percent inhibition concentration (IC50) value of 1.0 microM. When used to inhibit lysosomal acid sphingomyelinase, an approximately 50-fold greater concentration is required. In human peripheral monocytes, the compound inhibits bacterial lipopolysaccharide (LPS)-induced prostaglandin E2 production and LPS-induced interleukin-1beta production with IC50 values of 0.8 microM and 0.1 microM, respectively. In rat, p.o. administration of the compound has also been shown to inhibit carrageenin-induced paw edema. Thus, it is hoped that utility of scyphostatin as a pharmacological tool will contribute to our understanding of the role of ceramide in the cellular inflammation process.

Topics: Amides; Animals; Ascomycota; Carrageenan; Cell Membrane; Dinoprostone; Edema; Enzyme Inhibitors; Fibrosarcoma; Humans; Interleukin-1; Leukemia; Lipopolysaccharides; Lysosomes; Magnesium; Male; Mice; Monocytes; Pyrones; Rats; Rats, Wistar; Sphingomyelin Phosphodiesterase; Tumor Cells, Cultured